Navigation Links
Avalon Pharmaceuticals to Present at the American Association for,Cancer Research 2007 Annual Meeting

GERMANTOWN, Md., April 10, 2007 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. , today announced that AVN944 will be the subject of three poster presentations at the American Association for Cancer Research 2007 Annual Meeting to be held on April 14-18, 2007 in Los Angeles, Calif.

The first poster presented by Avalon, will review the data derived from the Avalon ongoing Phase I clinical trial of AVN944 for the treatment of hematological cancers. The poster is titled, "The Modulation of Gene Expression and Guanosine Pools by Inhibition of Inosine Monophosphate Dehydrogenase (IMPDH); correlating In Vitro Cell Resistance with Biomarker Response in Patient Samples from the Phase I Trial." This poster will provide data from clinical samples that correlate IMPDH inhibition, GTP pool suppression, and associated changes in tumor cell gene expression. The presentation will be Monday, April 16, 2007 from 8 a.m. until noon Pacific Time.

The second Avalon poster presentation is titled, "Antiangiogenic Properties of AVN944, A Potent Inhibitor of IMPDH." The poster will describe in vitro and in vivo experiments that reveal the effects of AVN944 on blood vessel formation. The presentation will be on Tuesday, April 17, 2007 from 8 a.m. until noon Pacific Time.

Another poster that will discuss AVN944 will be presented by the lab of Dr. Beverly Mitchell of Stanford University. The poster is titled, "GTP depletion induces translocation of TIF-IA and PAF53, inhibition of pre-rRNA synthesis and dislocation of nucleolar proteins." The presentation cites AVN944 as a compound that has effects on rRNA inhibition and nucleolar protein translocation. The poster presentation will be Tuesday, April 17, 2007 from 1 p.m. until 5 p.m. Pacific Time.

All three posters are in the Experimental and Molecular Therapeutics Poster Sessions.

AVN944 is an oral small molecule drug candidate that inhibits inosin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
2. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:11/24/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced today that Sergio Traversa , chief ... MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December ... Luxe Sunset Bel Air Hotel, which is located at ... . The presentation is scheduled for ...
(Date:11/24/2014)... , Nov. 24, 2014  AiCure, an artificial ... technology to monitor medication ingestion, has announced the ... and intervene with patients receiving medication as maintenance ... overdoses from prescription opiates have quadrupled in the ... per year than heroin, cocaine and benzodiazepines combined. ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... --  Empire Genomics today announced that it has ... portfolio for the Japanese market.  The deal represents Empire,s international ... "We are excited to have such a proven and expert ... access to our broad genomic product and service portfolio," said ...
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. ... Administration (FDA) for its Abbreviated New Drug Application (ANDA) for ... mg, 15 mg, and 20 mg. This product is the ... which is indicated for the treatment of schizophrenia and the ...
Cached Medicine Technology:Empire Genomics Chooses Funakoshi as Japan Distributor 2Mylan Launches Generic Version of Zyprexa® Tablets 2
(Date:11/23/2014)... 2014 Tbdress.com has recently announced ... on Nov. 28, 2014. The special offer will provide ladies ... is one of the world’s largest women’s dresses retailers, and ... People can enjoy great discounts on that day: Everything at ... delivery (for orders above $89). , People can use the ...
(Date:11/23/2014)... 2014 (HealthDay News) -- Close friends have more influence ... does, a new study says. "We,ve known ... an influence on individual alcohol use, but there are ... group and the friend group,s influence on those decisions," ... of Public Health, said in a university news release. ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... “BlackVue” was featured on NewsWatch as part of ... latest and coolest technology products available to consumers. Mallory ... the product review and shared with viewers how their ... car camera industry. , The need for in-car video ... find the one that’s right per consumer, especially considering ...
Breaking Medicine News(10 mins):Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Close Friends May Be Key to Teens' Drinking 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... Patients with obstructive sleep apnea (OSA) who ... of continuous positive airway pressure (CPAP) relieves them of ... the October 15 issue of the Journal of Clinical ... The Sleep Center at Universitys Community Hospital in Tampa, ...
... published in the October 15 issue of the Journal ... Sleepiness Questionnaire (CASQ), a new self-completed instrument to measure ... by James C. Spilsbury, PhD, of the Division of ... a subsample of 411 adolescents between 11-17 years of ...
... France, October 15 Sanofi Pasteur, the,vaccines ... partnership,with Institut Pasteur to develop a vaccine ... will have access to antigens,identified by Institut ... for the most deadly malaria infections. Sanofi ...
... SEATTLE, October 15 - ,Real Women, Real ... Recognition and Treatment in Women Around the World ... (IASP) has,declared 2008 the Global Year Against Pain in ... pain on women and the need for more,effective care. ...
... leading cancer organizations shows cancer death rates decreased on ... nearly twice the annual decrease of 1.1 percent per ... in the Annual Report to the Nation on the ... and Alaska Natives published online October 15, 2007 ( ...
... One of the most distressing aspects of Alzheimer,s disease is ... beginning of an inevitable mental decline. Researchers at the Stanford ... is a step toward giving people an answer two to ... , The test identifies changes in a handful of proteins ...
Cached Medicine News:Health News:New tool to assess excessive daytime sleepiness in adolescents published in JCSM 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 2Health News:Sanofi Pasteur and Institut Pasteur Team up Against Malaria 3Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 2Health News:International Association for the Study of Pain (IASP) Declares the Global Year Against Pain in Women 3Health News:Annual report to the nation finds cancer death rate decline doubling 2Health News:Annual report to the nation finds cancer death rate decline doubling 3Health News:Annual report to the nation finds cancer death rate decline doubling 4Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 2Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 3Health News:Blood test takes step toward predicting Alzheimer's risk, Stanford researchers find 4
... Hybrid Imaging in Cardiology ... unmatched imaging solutions in cardiology. ... quality coronary CT angiography imaging ... visibility. Symbia TruePoint SPECTCT ...
... with Tim™ (Total imaging matrix) technology ... and highest resolution at 3T. With ... advanced applications can now be translated ... with Tim is an excellent dual-purpose ...
... is a comprehensive medical billing software ... / multiple payer requirements of healthcare ... additional functionality to necessary to process ... specialties, such as trip reporting for ...
VisiClaim allows you to create, submit, track and manage your claims and reimbursements. VisiClaim gives you control over managing your claims and your billing....
Medicine Products: